Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17176546 | 0.88 | MEN1 (0.33) | CYP2D6SMN1; SMN2 | |
| SCHEMBL18459006 | 0.80 | — | — | |
| SCHEMBL18776457 | 0.77 | MEN1 (0.32) | CYP2D6SMN1; SMN2 | |
| SCHEMBL18416951 | 0.74 | MEN1 (0.31) | CYP2D6SMN1; SMN2 | |
| SCHEMBL7351993 | 0.74 | — | — | |
| SCHEMBL12674147 | 0.73 | S1PR4 (0.36) | — | |
| SCHEMBL19425763 | 0.71 | ALOX15 (0.46) | — | |
| SCHEMBL18203003 | 0.71 | OPRM1 (0.35) | — | |
| SCHEMBL3656482 | 0.71 | MAOB (0.31) | — | |
| SCHEMBL14856213 | 0.71 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255044-B1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | HARBIN PHARMACEUTICAL GROUP CO LTD GENERAL PHARMACEUTICAL FACTORY (CN) | 2020-04-01 | — | — | EP | disclosed |
| EP-3159341-B1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS PI3K INHIBITOR | CHAI TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| EP-3199530-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | Changzhou Yinsheng Pharmaceutical Co., Ltd. (CN) | 2017-08-02 | — | — | EP | disclosed |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-3170810-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-05-24 | — | — | EP | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| EP-3159341-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS PI3K INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2017-04-26 | — | — | EP | disclosed |
| EP-3159342-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/PI3K INHIBITOR | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-04-26 | — | — | EP | disclosed |
| EP-3147283-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | North China Pharmaceutical Company., Ltd. (CN) | 2017-03-29 | — | — | EP | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3130592-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | CYP2D6 2124/4885SMN1; SMN2 4465/4885 |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | CYP2D6 825/4885SMN1; SMN2 4871/4885 |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | CYP2D6 1262/4885SMN1; SMN2 3180/4885 |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | CYP2D6 784/4885SMN1; SMN2 2730/4885 |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | CYP2D6 2480/4885SMN1; SMN2 696/4885 |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | ME3, SSBP1, MDH2 | CYP2D6 1651/4885SMN1; SMN2 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.